Hengrui Medicine: Injection of Rituximab Included in Breakthrough Therapy Drug List

Hengrui Medicine announced that its subsidiary, Suzhou Cendek Medical BioPharmaceutical Co., Ltd., recently had its injection use of Fucanuzumab Monoclonal Antibody included in the list of breakthrough therapy products by the National Medical Products Administration Drug Evaluation Center. This marks the 10th indication for Fucanuzumab Monoclonal Antibody to receive breakthrough therapy certification.